AG
CGON icon

Algert Global’s CG Oncology CGON Stock Holding History

Algert Global’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Buy
+19,380
New +$1.1M 0.02% 809

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Algert Global's CGON Position: Q1 2026 in Review

Algert Global opened a new position in CG Oncology (CGON) in Q1 2026: 19,380 shares worth $1.31M. The stake represents 0.02% of the portfolio and ranks #809 among its holdings.

233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Algert Global held 19,380 shares of CG Oncology worth $1.31M as of Q1 2026.
  • CG Oncology was a new Algert Global position in Q1 2026.
  • CG Oncology made up 0.02% of Algert Global's portfolio in Q1 2026, its #809 holding.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.